FDA grants accelerated approval to J&J's Rybrevant Faspro for advanced head and neck cancer
The US Food and Drug Administration granted accelerated approval to Johnson & Johnson's Rybrevant Faspro for patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease has worsened after chemotherapy and immunotherapy. The FDA said its decision was based on a trial of 102 patients in which 42% of those treated saw their tumors shrink or disappear.